Nov 17, 2022

Featuring a slide presentation and related discussion from Dr Eytan Stein, including the following topics:

• Historical paradigms for treating newly diagnosed acute myeloid leukemia (AML) (0:00)
• Long-term findings and emerging results with venetoclax-based therapies for newly diagnosed and relapsed/refractory (R/R) AML (1:19)
• Efficacy and tolerability of oral decitabine/cedazuridine for patients with AML (19:27)
• Mechanism of action, activity and safety of magrolimab-based therapies for newly diagnosed and R/R disease (23:34)
• Sabatolimab: Mechanism of action and efficacy in combination with a hypomethylating agent (32:01)
• Therapeutic targeting of Menin and NPM1 mutations in AML; activity of entospletinib in combination with induction chemotherapy (37:29)

CME information and select publications